VHL

von Hippel-Lindau disease tumor suppressor · P40337 · VHL on Sugi Atlas →

87,958 patent compounds predicted against VHL, 67,813 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1273334	0.49	10/20
SCHEMBL3596862	0.72	9/20
SCHEMBL3593725	0.70	9/20
SCHEMBL3602056	0.69	9/20
SCHEMBL3586752	0.67	9/20
Hydrochloric Acid (SCHEMBL3617350)	0.59	9/20
SCHEMBL3597407	1.00	8/20
SCHEMBL3603539	1.00	8/20
Hydrochloric Acid (SCHEMBL3602778)	0.98	8/20
Hydrochloric Acid (SCHEMBL3594602)	0.98	8/20
Hydrochloric Acid (SCHEMBL3594795)	0.98	8/20
Hydrochloric Acid (SCHEMBL3588771)	0.98	8/20
Hydrochloric Acid (SCHEMBL3595086)	0.98	8/20
SCHEMBL3595668	0.83	8/20
Hydrochloric Acid (SCHEMBL3595675)	0.78	8/20
Hydrochloric Acid (SCHEMBL3597337)	0.77	8/20
Hydrochloric Acid (SCHEMBL3588053)	0.73	8/20
SCHEMBL3597325	0.71	8/20
SCHEMBL3622159	0.70	8/20
SCHEMBL3624835	0.69	8/20

Clinical trials — most relevant to VHL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease	PHASE2	RECRUITING
Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome	PHASE2	COMPLETED
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab	PHASE1/PHASE2	COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	PHASE2	COMPLETED
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors	PHASE2	RECRUITING
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)	PHASE1	COMPLETED
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome	PHASE1	COMPLETED
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients	nan	RECRUITING
Drivers of Hypoxia-induced Angiogenesis in Tumor Development	nan	UNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
MyVHL: Patient Natural History Study	nan	RECRUITING
Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?	nan	UNKNOWN
Data Collection Protocol for Patients With Von Hippel Lindau Disease	nan	RECRUITING
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes	nan	UNKNOWN
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma	nan	UNKNOWN
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome	nan	COMPLETED
Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System	nan	COMPLETED
Precision Medicine for Neurocutaneous Syndromes in Western China	nan	COMPLETED
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Quality of Life, Psychological Impact, and Care-related Challenges in Patients Affected by Von Hippel-Lindau Syndrome.	nan	ACTIVE_NOT_RECRUITING
Propranolol and Von Hippel-Lindau Disease	nan	RECRUITING
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples	nan	COMPLETED
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer	nan	ACTIVE_NOT_RECRUITING
MSD Belzutifan PAS	nan	WITHDRAWN
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	nan	RECRUITING
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a VHL binder may also engage these)

Protein	Name	Similarity
Q5Q9Z2	—	1.000	Q5Q9Z2 →
Q64259	—	0.998	Q64259 →
P40338	—	0.992	P40338 →
G3X9C2	—	0.961	G3X9C2 →
PML	Protein PML	0.959	landscape →
TERF2IP	Telomeric repeat-binding factor 2-interacting protein 1	0.957	landscape →
Q5R7L2	—	0.956	Q5R7L2 →
Q4R4I0	—	0.956	Q4R4I0 →
Q5RF77	—	0.955	Q5RF77 →
B0KWQ2	—	0.954	B0KWQ2 →
D3YYI7	—	0.953	D3YYI7 →
Q8NFZ0	—	0.953	Q8NFZ0 →
Q5MNU5	—	0.953	Q5MNU5 →
Q3UI43	—	0.953	Q3UI43 →
P97260	—	0.953	P97260 →
Q9DC63	—	0.953	Q9DC63 →
Q9D2C9	—	0.952	Q9D2C9 →
Q5XIJ6	—	0.952	Q5XIJ6 →
Q5EBM0	—	0.951	Q5EBM0 →
Q2TBA3	—	0.951	Q2TBA3 →
Q6DVA0	—	0.951	Q6DVA0 →
Q5GH73	—	0.950	Q5GH73 →
Q6L9W6	—	0.950	Q6L9W6 →
Q80Z30	—	0.950	Q80Z30 →
Q99MU3	—	0.950	Q99MU3 →
A4D1U4	—	0.950	A4D1U4 →
Q496Y0	—	0.950	Q496Y0 →
A2RRU4	—	0.950	A2RRU4 →
Q8C0R7	—	0.950	Q8C0R7 →
Q6NS60	—	0.949	Q6NS60 →